Financings in Brief: Possis Medical
This article was originally published in The Gray Sheet
Possis Medical: Net proceeds reach approximately $26.7 mil. from secondary offering which became effective Oct. 2 ("The Gray Sheet" Oct. 16, p. 6). Underwriters Dain Bosworth and John G. Kinnard & Co. exercised their over-allotment option for 221,258 shares beyond the initial 1.9 mil. shares offered, increasing the proceeds from the financing. The Minneapolis-based firm's AngioJet thrombectomy system commenced U.S. Phase I clinical trials in June for coronary applications. The final phase of U.S. trials for peripheral use and graft applications is under way and a 510(k) submission is planned for January 1996. The first European use of the coronary system was announced Nov. 2...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.